Facial hypertrichosis induced by cetuximab, an anti-EGFR monoclonal antibody [8]

Archives of Dermatology

Volumn 142, Issue 12, 2006, Pages 1656-1657

  Kerob, Delphine ^a   Dupuy, Alain ^b   Reygagne, Pascal ^b   Levy, Annabelle ^b   Morel, Patrice ^b   Bernard, Bruno A ^b   Lebbé, Céleste ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; PACLITAXEL;

AGED; ANAMNESIS; CARCINOMA; CASE REPORT; CLINICAL FEATURE; DISTRESS SYNDROME; FEMALE; HUMAN; HYPERTRICHOSIS; LETTER; POROCARCINOMA; PRIORITY JOURNAL;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; FACE; FEMALE; HUMANS; HYPERTRICHOSIS; LEG; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS;

EID: 33845689865     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.12.1656     Document Type: Letter

References (5)

1. Dueland S, Lund-Johansen F, Ostenstad B, Magne Tveit K. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol. 2003;42:345-346.
2. Pascual JC, Banuls J, Belinchon I, Blanes M, Massuiti B. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol. 2004;151:1111-1112.
3. Montagut C, Grau JJ, Grimalt R, Codony J, Ferrando J, Albanell J. Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. J Clin Oncol. 2005;23:5273-5275.
4. Albanell J, Rajo F, Averbuch S. Pharmacodynamic studies in the epidermal growth factor receptor inhibitor ZD in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110-124.
5. Murillas R, Larcher F, Conti CJ, Santos M, Ullrich A, Jorcano JL. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J. 1995;14:5216-5223.